ASTRAZEN — Astrazeneca Pharma India Balance Sheet
0.000.00%
- IN₹222.68bn
- IN₹217.51bn
- IN₹17.16bn
Annual balance sheet for Astrazeneca Pharma India, fiscal year end - March 31st, INR millions except per share, conversion factor applied.
2021 March 31st | 2022 March 31st | 2023 March 31st | 2024 March 31st | 2025 March 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | ARS | ARS | ARS | ARS | PRESS |
Standards: | IAS | IAS | IAS | IAS | — |
Status: | Final | Final | Final | Final | Final |
Cash | |||||
Cash and Equivalents | |||||
Short Term Investments | |||||
Cash and Short Term Investments | 3,523 | 4,485 | 5,003 | 5,056 | 5,525 |
Net Total Accounts Receivable | |||||
Net Total Receivables | 978 | 1,050 | 1,325 | 1,854 | 1,852 |
Total Inventory | |||||
Prepaid Expenses | |||||
Total Other Current Assets | |||||
Total Current Assets | 6,188 | 7,057 | 8,355 | 9,327 | 13,424 |
Gross Property, Plant And Equipment | |||||
Accumulated Depreciation | |||||
Net Property, Plant And Equipment | 850 | 767 | 702 | 648 | 636 |
Net Intangible Assets | |||||
Long Term Investments | |||||
Long Term Notes Receivable | |||||
Other Long Term Assets | |||||
Total Assets | 7,747 | 8,566 | 9,849 | 10,780 | 15,181 |
Accounts Payable | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Current Portion of Long Term Debt / Capital Leases | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 3,035 | 3,327 | 3,839 | 3,571 | 7,030 |
Capital Lease Obligations | |||||
Total Long Term Debt | |||||
Total Debt | |||||
Total Other Liabilities | |||||
Total Funded Status | |||||
Total Liabilities | 3,185 | 3,452 | 3,962 | 3,661 | 7,478 |
Common Stock | |||||
Retained Earnings (Accumulated Deficit) | |||||
ESOP Debt Guarantee | |||||
Total Equity | 4,562 | 5,114 | 5,887 | 7,119 | 7,704 |
Total Liabilities & Shareholders' Equity | 7,747 | 8,566 | 9,849 | 10,780 | 15,181 |
Total Common Shares Outstanding |